2025 FDA Q1 Drug Approvals and Launches to Watch: Stelara Biosimilars, Non-Opioid Pain Relief & More
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh The first quarter of 2025 has brought […]
Articles
GLP-1s, Weight Loss & Rising Drug Spend: How Employers Can Adapt
By Beckie Fenrick, PharmD, MBA; Emily Crisano, PharmD, RPh; and Jason Peterson, RPh The market for GLP-1 receptor agonists is
The Power of Independent PBM Rebate Reconciliation
By Bethany Hruschak, Senior Manager, Pricing and Analytics Managing pharmacy costs is an essential but complex task for organizations striving
Navigating the Changing Landscape of Pharmacy Rebates: What Self-Funded Employers Need to Know
By Beckie Fenrick, PharmD, MBA Navigating the evolving rebate landscape requires in-depth expertise, especially as regulatory changes and PBM strategies
The Biosimilar Shift: How New Options for Stelara and Humira are Reshaping Specialty Care for Payers
The biosimilar landscape is continuing to rapidly evolve, and 2025 marks a pivotal year for payers seeking cost-saving opportunities. With Stelara biosimilars making their debut and Humira biosimilars continuing to gain traction, plan sponsors will have more options than ever to control costs while ensuring members have access to the essential therapies they need.
Evaluating the Efficacy and Value Proposition of Modern Diabetic Drugs- Insights for Brokers and Their Groups
As the pipeline of drugs for diabetes management continues to grow, benefit partners and advisors and the employer groups they serve are positioned to influence significant decisions that will impact healthcare spending.
Inside Navion: Employee Voices – Beckie Fenrick
Beckie Fenrick, Chief Pharmacy Officer, leverages her expertise to help health plans, employers, and PBMs achieve better pharmacy outcomes.
